Traws Pharma, Inc. financial data

Symbol
TRAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
12 Penns Trail, Newtown, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Onconova Therapeutics, Inc. (to 4/1/2024), ONCONOVA THERAPEUTICS INC (to 5/26/2009)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 185 % -49.9%
Operating Margin -62.6K % -556%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.03M shares -85.6%
Common Stock, Shares, Outstanding 3.03M shares -85.6%
Entity Public Float 24.6M USD -10.5%
Common Stock, Value, Issued 30K USD -85.7%
Weighted Average Number of Shares Outstanding, Basic 962K shares +14.5%
Weighted Average Number of Shares Outstanding, Diluted 962K shares +14.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 226K USD 0%
Revenue from Contract with Customer, Excluding Assessed Tax 57K USD 0%
Research and Development Expense 9.26M USD -31.3%
General and Administrative Expense 10.9M USD +20.7%
Operating Income (Loss) -142M USD -556%
Net Income (Loss) Attributable to Parent -8.48M USD -78.8%
Earnings Per Share, Basic -8.7 USD/shares -36.4%
Earnings Per Share, Diluted -8.7 USD/shares -36.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6M USD -46.6%
Other Assets, Current 347K USD +14.5%
Assets, Current 8.92M USD -67%
Property, Plant and Equipment, Net 12K USD -53.8%
Other Assets, Noncurrent 1K USD 0%
Assets 8.94M USD -67%
Accounts Payable, Current 5.47M USD -11%
Employee-related Liabilities, Current 578K USD -32.3%
Accrued Liabilities, Current 2.65M USD -19.7%
Contract with Customer, Liability, Current 226K USD 0%
Liabilities, Current 8.35M USD -13.7%
Contract with Customer, Liability, Noncurrent 2.62M USD -7.94%
Liabilities 11M USD -12.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -33K USD -10%
Retained Earnings (Accumulated Deficit) -619M USD -29.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.03M USD -114%
Liabilities and Equity 8.94M USD -67%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.42M USD +2.62%
Common Stock, Shares Authorized 250M shares +100%
Common Stock, Shares, Issued 3.03M shares -85.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.43M USD +2.34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.41M USD -78.6%
Deferred Tax Assets, Valuation Allowance 174M USD +2.44%
Deferred Tax Assets, Gross 174M USD +2.44%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.48M USD -78.8%
Property, Plant and Equipment, Gross 84K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 74M USD +0.87%
Preferred Stock, Shares Issued 7.44K shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 7.44K shares
Depreciation, Depletion and Amortization 4K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.39M USD +6.93%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%